MYC and type 2 diabetes mellitus: While analyzing the overexpressed miRNAs in pdEs from GDM, hsa-miR-320b became a interested candidate as it was demonstrated to be differentially expressed in plasma of prediabetes and newly diagnosed type 2 diabetes (20), and inhibited the proliferation of human cancer cells through targeting c-myc (21).